Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Opebacan in Myeloablative Allogeneic HSCT
NCT00454155Phase 2Terminated
- Sponsor
- XOMA
- Start
- Feb 2007
- Primary completion
- Jun 2010
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of opebacan in graft-versus-host disease (GVHD), sponsored by XOMA. Started Feb 2007; status: terminated.
02
Drugs
opebacan
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT00454155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00454155.